# An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

> **NCT02398461** · PHASE1 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 27 (actual)

## Conditions studied

- Multiple Sclerosis, Acute Relapsing

## Interventions

- **DRUG:** rHIgM22
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02398461
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2017-09
- **Final completion:** 2017-09-21
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2018-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02398461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02398461, "An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02398461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*